	US 12,201,607 B2
	Compositions and methods for preventing and treating conditions
Jason M. Criscione, Chelmsford, MA (US)
Assigned to Ansella Therapeutics, Inc., Lowell, MA (US)
Filed by Ansella Therapeutics, Inc., Lowell, MA (US)
Filed on May 5, 2020, as Appl. No. 16/867,045.
Application 16/867,045 is a continuation of application No. 16/220,517, filed on Dec. 14, 2018, granted, now 10,668,046.
Claims priority of provisional application 62/609,127, filed on Dec. 21, 2017.
Claims priority of provisional application 62/607,286, filed on Dec. 18, 2017.
Prior Publication US 2020/0360340 A1, Nov. 19, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/355 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/107 (2006.01); A61K 31/41 (2006.01); A61K 45/06 (2006.01); A61P 17/02 (2006.01); A61P 27/02 (2006.01); A61P 39/06 (2006.01)

CPC A61K 31/355 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0034 (2013.01); A61K 9/06 (2013.01); A61K 9/107 (2013.01); A61K 31/41 (2013.01); A61P 17/02 (2018.01); A61P 27/02 (2018.01); A61P 39/06 (2018.01); A61K 45/06 (2013.01)]

10 Claims

1. A method for treating a vaginal condition in a subject, comprising:

applying to a tissue surface a composition comprising a stable water-in-silicone emulsion having a continuous silicone phase and an aqueous phase,

wherein the emulsion comprises a non-silicone emulsifier comprising cholesterol or a cholesterol derivative at a concentration from about 0.1% to about 4% by weight of the total weight of the composition and a sorbitan ester,

wherein the composition does not utilize a silicone-based emulsifier,

wherein the pH of the composition is from about 3 to about 5,

wherein the composition has an osmolarity of about 200 to about 500 mOsm/kg,

wherein the composition comprises glycogen, and

wherein the composition is used in an amount effective to treat said vaginal condition in the subject, wherein said vaginal condition comprises vulvar and vaginal atrophy (VVA).